You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 296 No. 13, October 4, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Viral Infections
 •Drug Therapy
 •Drug Therapy, Other
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Shift Shown in Influenza A Adamantane Resistance

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: With current concerns about a global influenza pandemic, the study by Dr Bright and colleagues1 and the accompanying editorial by Drs Weinstock and Zuccotti2 discussing accelerating adamantane resistance in community-acquired influenza A are alarming. The US Centers for Disease Control and Prevention (CDC) has done an effective job of disseminating this information and instructing clinicians to substitute neuraminidase inhibitors (NIs) as treatment and chemoprophylaxis for influenza this year.3 However, if overuse of adamantane derivatives has resulted in an increase of resistance in US isolates from 1.9% in 2004 to 92.3% in December 2005, I suggest that we should make every attempt to preserve the efficacy of NIs by using them judiciously and with restraint.

While the CDC recommends priority use of influenza antiviral medications for "any person experiencing a potentially life-threatening influenza-related illness" and for "any person at high risk for serious complications of influenza and who . . . [Full Text of this Article]

Katherine M. Shea, MD, MPH
tkmjshea@mindspring.com
North Carolina State University
Raleigh



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Shift Shown in Influenza A Adamantane Resistance
Raj C. Shah
JAMA. 2006;296(13):1585-1586.
EXTRACT | FULL TEXT  

Shift Shown in Influenza A Adamantane Resistance—Reply
David K. Shay, Rick A. Bright, Michael Shaw, Nancy J. Cox, and Alexander I. Klimov
JAMA. 2006;296(13):1586-1587.
EXTRACT | FULL TEXT  

Shift Shown in Influenza A Adamantane Resistance—Reply
David M. Weinstock and Gianna Zucotti
JAMA. 2006;296(13):1587.
EXTRACT | FULL TEXT  

Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United States
Rick A. Bright, David K. Shay, Bo Shu, Nancy J. Cox, and Alexander I. Klimov
JAMA. 2006;295(8):891-894.
ABSTRACT | FULL TEXT  

Adamantane Resistance in Influenza A
David M. Weinstock and Gianna Zuccotti
JAMA. 2006;295(8):934-936.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.